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ABSTRACT

MATERIALS AND METHODS

GLUTATHIONE DEPLETION WITH CHRONIC MPH

Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 11% of
children in the US alone. Methylphenidate (MPH) is the most commonly prescribed drug for the
treatment of ADHD. Given the fact that ADHD symptoms persist in up to 50% of patients, many
children receive MPH from childhood to early adulthood. Unfortunately, most of the scientific
literature focuses on the short-term consequences of MPH, even though individuals are taking MPH for
many years. MPH acts by blocking dopamine (DA) transporters and norepinephrine transporters,
preventing the reuptake of these catecholamines following release. Previous research has shown that
long-term exposure to MPH causes dopaminergic neurons within the nigrostriatal pathway to be more
sensitive to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We
hypothesize that oxidative stress caused by the spontaneous oxidation of the excess DA in the synaptic
cleft is what’s rendering dopaminergic neurons within the nigrostriatal pathway to be more sensitive
to MPTP. Adolescent male Swiss-Webster mice were divided into three cohorts and administered
either saline (control), 1 mg/kg MPH (normal dose) or 10 mg/kg (abusive dose) via intraperitoneal (IP)
injections for 12 weeks. Mice were injected twice daily, Monday through Friday, mimicking a schoolweek dosing schedule. After 12 weeks, all animals received a drug washout period of 7 days. Then, half
of each cohort was treated with MPTP (4 x 20mg/kg, every 2 hours), while the other half was
administered 4 injections of sterile saline. Seven days after MPTP or saline treatment, the mice were
sacrificed, brains were removed, and the substantia nigra (SN) and striatum (STR) were collected.
Oxidative stress related to increased DA levels was determined using the glutathione assay to measure
glutathione (GSH) content and near-infrared fluorescence dot blots to measure free and protein-bound
ortho-quinones. GSH is an important antioxidant and thus its depletion would be indicative of
oxidative stress. Additionally, since DA may be oxidized to a quinone, increases in free and proteinbound ortho-quinones also indicate oxidative stress. Interestingly, we observed a significant decrease
in GSH as the dose of MPH increased with both saline and MPTP samples. Furthermore, there was a
significant increase in quinones as the dose of MPH increased. In conclusion, it appears that long-term
exposure to MPH sensitizes dopaminergic neurons within the nigrostriatal pathway to oxidative stress,
rendering them vulnerable to further insults, such as MPTP exposure. As such, these studies provide
insight into the risks of long-term psychostimulant exposure.

Purpose: To determine if MPTP susceptibility due to long-term exposure to MPH is correlated with
oxidative stress in the substantia nigra and the striatum.

Glutathione is an important antioxidant that protects against dopamine toxicity and thus its
depletion would be indicative of oxidative stress.
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Excess dopamine may be autooxidized into quinones which will contribute to oxidative
stress and cause cellular damage. Thus, increases in free and protein-bound quinones
should be seen when oxidative stress occurs.
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Figure 5. The amount of free and protein-bound quinones in the STR (n=4). One-way ANOVA followed by
Fisher’s post-hoc test.
*p<0.05 vs 1 mg/kg MPH + Saline; **p<0.05 vs Saline + Saline; #p<0.05 vs 10 mg/kg MPH + Saline
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CONCLUSIONS
There was a significant decrease in GSH seen in the striatum as the dose of MPH was increased with
both saline and MPTP samples. Furthermore, there was a significant increase in quinones observed
in the striatum and substantia nigra as the dose of MPH increased. In conclusion, it appears that
long-term exposure to MPH sensitizes dopaminergic neurons within the nigrostriatal pathway to
oxidative stress, rendering them vulnerable to further insults, such as MPTP exposure.

FUTURE DIRECTIONS
Previous studies investigating MPH use predominantly focus on the effect of MPH only in male
subjects; little is known about the consequences of MPH exposure to females. Although estrogen has
been shown to be protective against MPTP3, females have been shown to be at a greater risk for
developing neurodegenerative disorders such as Parkinson’s disease with repeated exposure to other
psychostimulants (amphetamines)4. Therefore, we are interested in determining the extent of
oxidative stress within the nigrostriatal pathway of cycling females after long-term exposure to MPH.
These experiments will provide insight into how chronic MPH affects dopaminergic neurons within the
nigrostriatal pathway as well as insight into how estrogen influences the effects of chronic MPH in the
female brain. Our hypothesis is that long-term exposure to MPH will reduce the neuroprotective
actions of estrogen against MPTP and sensitize the female animals to its neurotoxic effects.
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Figure 2. MPTP mechanism (2). MPTP targets and
destroys dopaminergic neurons resulting in Parkinson’slike symptoms. MPTP crosses the blood-brain barrier
where it is oxidized by MAO to MPP+ in glial cells. Glial
cells release MPP+, and MPP+ is taken up by neurons
through the dopamine transporter. MPP+ then inhibits
complex I, leading to cell death.
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In our study, adolescent male Swiss-Webster mice were divided into three cohorts and administered
either saline (control), 1 mg/kg MPH (normal dose) or 10 mg/kg (abusive dose) via intraperitoneal (IP)
injections for 12 weeks. Mice were injected twice daily, Monday through Friday, mimicking a schoolweek dosing schedule. After 12 weeks, all animals received a drug washout period of 7 days. Then,
half of each cohort was treated with MPTP (4 x 20 mg/kg, every 2 hours), while the other half was
administered 4 injections of sterile saline. Seven days after MPTP or saline treatment, the mice were
sacrificed, brains were removed, and the substantia nigra (SN) and striatum (STR) were
collected. Oxidative stress related to increased DA levels was determined using the glutathione assay
to measure glutathione (GSH) content and near-infrared fluorescence dot blots to measure free and
protein-bound ortho-quinones.

0

0

-C:

2.0

B<od-b<ruobruri*

•
-

( I)

2.51

monoamines in the synaptic cleft
By interfering with the electron transport chain, MPTP
(1).
inhibits mitochondrial metabolism, causing a build up of free
radicals and leading to dopaminergic cell death. The increase in oxidative stress
and subsequent loss of dopaminergic neurons and induces Parkinsonian symptoms. During
oxidative stress associated with elevated dopamine, quinone levels increase and glutathione
levels decrease. Therefore, oxidative stress was measured using a glutathione assay and a nearinfrared fluorescence dot blot (used to measure quinone production).
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INTRODUCTION

We hypothesize that oxidative stress caused by the spontaneous
oxidation of the excess dopamine following long-term MPH
Figure 1. MPH blocks the reuptake
treatment is rendering dopaminergic neurons within the
of dopamine and norepinephrine,
nigrostriatal pathway to be more sensitive to MPTP.
increasing the levels of these
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The primary mechanism of action of MPH is to prevent the
reuptake of dopamine and norepinephrine by blocking presynaptic transporters on monoamininergic neurons (Fig. 1).
Previous research has shown that long-term exposure to MPH
causes dopaminergic neurons within the nigrostriatal pathway
to be more sensitive to the Parkinsonian toxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Figure 3. Glutathione content in
the striatum (n=4). One-way
ANOVA followed by Fisher’s posthoc test.
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Figure 6. The amount of free and protein-bound quinones in the SN (n=4). One-way ANOVA followed by
Fisher’s post-hoc test .
*p<0.05 vs Saline + Saline; **p<0.05 vs 1 mg/kg MPH + MPTP; ***p<0.05 vs Saline + Saline; #p<0.05 vs 1
mg/kg MPH + MPTP; ##p<0.05 vs Saline + MPTP
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